Almost half of the people screened were given the flick from our trial, so they really did go for those who standard care doesn't seem to help.
And yet we still have fantastic overall improvement rates.
We could easily end up with a 100% plus better rate of improvement over the control arm.
Ann: CEO presentation to Broker Meets Biotech - Perth, page-18
-
- There are more pages in this discussion • 69 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
